Advertisement
Screener

ALNYLAM PHARMACEUTICALS, INC. (ALNY) Increase (Decrease) in Income Taxes Payable

2.8 / 5 stars · 68/120 Roast Me

ALNYLAM PHARMACEUTICALS, INC. Increase (Decrease) in Income Taxes Payable

ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Increase (Decrease) in Income Taxes Payable of -$5.52 million for the 12-month period ending 2010-12-31, per its 10-K filed 2013-02-19.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2013-02-19

  • ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in income taxes payable for the quarter ending 2010-12-31 was $30.00K, a 99.31% decline year-over-year.
  • ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in income taxes payable for the quarter ending 2010-09-30 was $1.00K.
  • ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in income taxes payable for the quarter ending 2010-06-30 was -$1.00K.
  • ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in income taxes payable for the quarter ending 2010-03-31 was -$5.55M.
  • ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in income taxes payable for fiscal 2010 was -$5.52M.
  • ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in income taxes payable for fiscal 2009 was -$467.00K, a 117.87% decline from fiscal 2008.
  • ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in income taxes payable for fiscal 2008 was $2.61M.
Period endIncrease (Decrease) in Income Taxes Payable 3 monthIncrease (Decrease) in Income Taxes Payable 6 monthIncrease (Decrease) in Income Taxes Payable 9 monthIncrease (Decrease) in Income Taxes Payable 12 month
2010-12-31$30.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19
$31.00K
derived: sum of 2 quarters · filed 2013-02-19
$30.00K
derived: sum of 3 quarters · filed 2013-02-19
-$5.52M
10-K · filed 2013-02-19
2010-09-30$1.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03
$0.00
derived: sum of 2 quarters · filed 2011-11-03
-$5.55M
10-Q · filed 2011-11-03
-$1.22M
derived: sum of 4 quarters · filed 2012-02-13
2010-06-30-$1.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-03
-$5.55M
10-Q · filed 2011-08-03
-$1.22M
derived: sum of 3 quarters · filed 2012-02-13
-$1.73M
derived: sum of 4 quarters · filed 2012-02-13
2010-03-31-$5.55M
10-Q · filed 2011-05-05
-$1.22M
derived: sum of 2 quarters · filed 2012-02-13
-$1.73M
derived: sum of 3 quarters · filed 2012-02-13
2009-12-31$4.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-13
$3.81M
derived: sum of 2 quarters · filed 2012-02-13
-$467.00K
10-K · filed 2012-02-13
2009-09-30-$512.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-04
-$4.79M
10-Q · filed 2010-11-04
2009-06-30-$4.28M
10-Q · filed 2010-08-05
2008-12-31$2.61M
10-K · filed 2011-02-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10